Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss

Key Takeaways AGIO reported Q4 loss of $1.85 per share and $20M in revenues, topping estimates.Pyrukynd U.S. sales rose 49% year over year, while Aqvesme had a strong launch in December 2025.AGIO eyes FDA talks in Q1 2026 for mitapivat in SCD after mixed phase III RISE UP data.Agios Pharmaceuticals (AGIO) reported a loss of $1.85 per share in the fourth quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.97. In the year-ago quarter, the company had reported a loss of $1.74 per share. ...